Andrei Gennadievich Goncharov

Andrei Gennadievich Goncharov

Auto-generated profile, based on publicly available information

Andrei Gennadievich Goncharov

Immanuel Kant Baltic Federal University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2015 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
VSVictor Seledtsov
Victor Seledtsov
AGAg Goncharov
Ag Goncharov
GSGalina Victorovna Seledtsova
Galina Victorovna Seledtsova
The immune system exerts both tumor-destructive and tumor-protective functions. Mature dendritic cells (DCs), classically activated macrophages (M1), granulocytes, B lymphocytes, aβ and ɣδ T lymphocytes, natural killer T (NKT) cells, and natural killer (NK) cells may be implicated in antitumor immunoprotection. Conversely, tolerogenic DCs, alternatively activated macrophages (M2), myeloid-derived suppressor cells (MDSCs), and regulatory T (Tregs) and B cells (Bregs) are capable of suppressing antitumor immune responses. Anti-cancer vaccination is a useful strategy to elicit antitumor immune responses, while overcoming immunosuppressive mechanisms. Whole tumor cells or lysates derived thereof hold more promise as cancer vaccines than individual tumor-associated antigens (TAAs), because vaccinal cells can elicit immune responses to multiple TAAs. Cancer cell-based vaccines can be autologous, allogeneic or xenogeneic. Clinical use of xenogeneic vaccines is advantageous in that they can be most effective in breaking the preexisting immune tolerance to TAAs. To potentiate immunotherapy, vaccinations can be combined with other modalities that target different immune pathways. These modalities include 1) genetic or chemical modification of cell-based vaccines; 2) cross-priming TAAs to T cells by engaging dendritic cells; 3) T-cell adoptive therapy; 4) stimulation of cytotoxic inflammation by non-specific immunomodulators, toll-like receptor (TLR) agonists, cytokines, chemokines or hormones; 5) reduction of immunosuppression and/or stimulation of antitumor effector cells using antibodies, small molecules; and 6) various cytoreductive modalities. The authors envisage that combined immunotherapeutic strategies will allow for substantial improvements in clinical outcomes in the near future.

1 March 2018 in Cellular Immunology
Verified
Journal Article
Closed access
VMVladimir Vladimirovich Malashchenko
Vladimir Vladimirovich Malashchenko
MMMaxsim Evgenievich Meniailo
Maxsim Evgenievich Meniailo
VSViacheslav Anatolievich Shmarov
Viacheslav Anatolievich Shmarov
NGNatalia Dinislamovna Gazatova
Natalia Dinislamovna Gazatova
OMOlga Borisovna Melashchenko
Olga Borisovna Melashchenko
VSVictor Seledtsov
Victor Seledtsov

9 October 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
Daria Shunkina (Skuratovskaia)Daria Shunkina (Skuratovskaia)
Daria Shunkina (Skuratovskaia)
MVMaria Vulf
Maria Vulf
OKOlga Khaziakhmatova
Olga Khaziakhmatova
VMVladimir Malashchenko
Vladimir Malashchenko
AKAleksandra Komar
Aleksandra Komar
LLLarisa Litvinova
Larisa Litvinova
Chronic inflammation may not begin with local tissue disorders, such as hypoxia, but with the accumulation of critically activated macrophages in one site. The purpose of this review is to analyze the data reported in the scientific literature on the features of the functions of macrophages and their contributions to the development of pathology in various tissues during aseptic inflammation in obese subjects. In individuals with obesity, increased migration of monocytes from the peripheral blood to various tissues, the proliferation of resident macrophages and a change in the balance between alternatively activated anti-inflammatory macrophages (M2) and pro-inflammatory classically activated macrophages (M1) towards the latter have been observed. The primary cause of some metabolic pathologies has been precisely identified as the recruitment of macrophages with an altered phenotype, which is probably typical for many other pathologies. Recent studies have identified phenotypes, such as metabolically activated M (MMe), oxidized (Mox), hemoglobin-related macrophages (Mhem and MHb), M4 and neuroimmunological macrophages (NAM, SAM), which directly and indirectly affect energy metabolism. The high heterogeneity of macrophages in tissues contributes to the involvement of these cells in the development of a wide range of immune responses, including pathological ones. The replenishment of tissue-specific macrophages occurs at the expense of infiltrating monocyte-derived macrophages (MoMFs) in the pathological process. The origin of MoMFs from a general precursor retains their common regulatory mechanisms and similar sensitivity to regulatory stimuli. This makes it possible to find universal approaches to the effect on these cells and, as a consequence, universal approaches for the treatment of various pathological conditions.

1 September 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
MMMaksim Evgenievich Meniailo
Maksim Evgenievich Meniailo
VMVladimir Vladimirovich Malashchenko
Vladimir Vladimirovich Malashchenko
VSViacheslav Anatolievich Shmarov
Viacheslav Anatolievich Shmarov
NGNatalia Dinislamovna Gazatova
Natalia Dinislamovna Gazatova
OMOlga Borisovna Melashchenko
Olga Borisovna Melashchenko
VSVictor Seledtsov
Victor Seledtsov

1 December 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
VSVictor Seledtsov
Victor Seledtsov
AGA.G. Goncharov
A.G. Goncharov
GSGalina Victorovna Seledtsova
Galina Victorovna Seledtsova

1 October 2016 in European Cytokine Network
Verified
Journal Article
Closed access
VSVyacheslav A. Shmarov
Vyacheslav A. Shmarov
VMVladimir V. Malashchenko
Vladimir V. Malashchenko
MMMaksim E. Meniailo
Maksim E. Meniailo
NGNatalia D. Gazatova
Natalia D. Gazatova
NTNatalia Todosenko
Natalia Todosenko
VSVictor Seledtsov
Victor Seledtsov
СD3+ T lymphocytes were isolated by positive magnetic separation from the peripheral blood of healthy donors. In the absence of any additional activating stimuli, interleukin-7 (IL-7) was shown to augment the levels of T cells expressing CD25 activation marker both in СD4-positive and in CD4-negative effector memory (CD45RA-CD197-) T cell subsets, as well as in terminally differentiated (CD45RA+CD197-) Т cells, without significantly affecting the activation status of naive (CD45RA+CD197+) and central memory (CD45RA-CD197+) T cells. In addition, IL-7 noticeably enhanced the production of IL-2, interferon-γ (IFN-γ), and IL-10, but not IL-4, in T cells. The direct effects of IL-7 on T cell activation induced in vitro by MACSiBead™ particles coated with CD2, CD3, and CD28 antibodies (Abs) were also investigated. Upon cell activation, IL-7 significantly augmented the levels of CD25+ T cells in naive (CD45RA+CD197+), central memory (CD45RA-CD197+), and effector memory (CD45RA-CD197-) T-cell compartments. In addition, IL-7 facilitated activation of СD4- (but not CD4+) terminally differentiated effector (CD45RA+CD197-) Т cells. Finally, IL-7 was found to upregulate the production of IL-2, IFN-γ, IL-4, and IL-10 by activated T cells. In conclusion, we speculate that IL-7 is capable of enhancing functional T cell activity without causing significant functional inbalance between various T cell subsets.